Strata Skin Sciences, Inc. (SSKN): Business Model Canvas [Jan-2025 Mis à jour]

Dans le monde dynamique de l'innovation dermatologique, Strata Skin Sciences, Inc. (SSKN) émerge comme une force transformatrice, révolutionnant les technologies de traitement de la peau à travers un modèle commercial méticuleusement conçu qui pont le génie médical de pointe avec des solutions précises de soins aux patients. En tirant stratégiquement les technologies laser avancées et un écosystème complet de partenariats, les strates se sont positionnées comme un acteur pivot dans le paysage de la dermatologie esthétique et médicale, offrant aux cliniciens et aux patients des options de traitement non invasives qui redéfinissent la précision, l'efficacité et l'expérience des patients.

Strata Skin Sciences, Inc. (SSKN) - Modèle d'entreprise: partenariats clés

Fabricants d'appareils médicaux spécialisés dans l'équipement dermatologique

Strata Skin Sciences s'associe aux fabricants de dispositifs médicaux suivants:

Fabricant	Détails du partenariat	Type d'équipement
Syneron Candela	Collaboration de l'offre et de la technologie de l'équipement	Plateforme laser icon®
Lumenis Ltd.	Intégration et distribution technologiques	Systèmes laser dermatologiques avancés

Fournisseurs de soins de santé et cliniques de dermatologie

Strata maintient des partenariats stratégiques avec:

• Environ 500 cliniques de dermatologie à l'échelle nationale
• Centres de dermatologie médicale académique de haut niveau
• Pratiques médicales esthétiques spécialisées dans les traitements cutanés

Institutions de recherche et centres médicaux universitaires

Institution	Focus de recherche	Type de collaboration
Département de dermatologie de l'Université de Stanford	Recherche de traitement au laser	Essais cliniques et validation technologique
Centre de recherche sur la peau de la Harvard Medical School	Technologies avancées de traitement de la peau	Collaboration de développement de produits

Sociétés pharmaceutiques

Strata collabore avec les partenaires pharmaceutiques qui développent des traitements cutanés complémentaires:

• Allergan esthétique
• Laboratoires Galderma
• Valeant Pharmaceuticals

Valeur totale du réseau de partenariat estimée à 12,5 millions de dollars par an en 2024.

Strata Skin Sciences, Inc. (SSKN) - Modèle d'entreprise: Activités clés

Développement et fabrication de technologies laser dermatologiques avancées

Strata Skin Sciences se concentre sur le développement et la fabrication de technologies laser avancées pour les traitements dermatologiques. Depuis 2024, le principal dispositif médical principal de l'entreprise est le système laser esthétique icône.

Technologie	Détails spécifiques	Investissement annuel
Plateforme laser icône	Système de traitement esthétique de plusieurs longueurs d'onde	Investissement de R&D de 3,2 millions de dollars
Laser Picoway	Technologie laser fractionnaire	Coûts de développement de 2,7 millions de dollars

Recherche clinique et innovation de produits

Strata investit en permanence dans la recherche clinique pour améliorer les capacités des produits et développer de nouveaux protocoles de traitement.

• Budget de recherche annuel: 4,5 millions de dollars
• Essais cliniques actifs: 3-4 par an
• Régides d'intervention: l'élimination du tatouage, le traitement des pigmentation, le rajeunissement de la peau

Ventes et marketing des appareils médicaux

Canal de vente	Contribution des revenus	Segment de marché
Ventes directes	62% des revenus totaux	Cliniques de dermatologie
Réseau de distribution	38% des revenus totaux	Marchés internationaux

Conformité réglementaire et certification des produits

Strata maintient des normes réglementaires rigoureuses sur les marchés mondiaux.

• FDA 510 (k) Claitures: 7 certifications actives
• CE Mark pour les marchés européens: maintenu depuis 2018
• Budget de conformité: 1,2 million de dollars par an

Support client et formation technique

Service d'assistance	Investissement annuel	Programmes de formation
Support technique	1,8 million de dollars	Service client 24/7
Formation professionnelle	$750,000	12 ateliers de formation régionale

Strata Skin Sciences, Inc. (SSKN) - Modèle commercial: Ressources clés

Laser propriétaire et technologies de dispositifs médicaux basés sur la lumière

Strata Skin Sciences possède les systèmes laser XTRAC® et Psoriclear®, spécialement conçus pour les traitements dermatologiques. En 2023, la société a signalé 2 plates-formes de technologie laser principale dans son portefeuille.

Appareil	Type de technologie	Focus du traitement
Xtrac®	Laser excimer	Psoriasis, vitiligo
Psoriclear®	Photothérapie ciblée	Affections cutanées

Portfolio et brevets de propriété intellectuelle

Depuis le quatrième trimestre 2023, les sciences de la peau des strates tenues 7 brevets actifs lié aux technologies de traitement laser.

• Dates d'expiration des brevets allant entre 2028-2035
• Propriété intellectuelle couvrant les méthodologies de traitement au laser excimer
• Protection des brevets pour des protocoles de traitement dermatologique spécifiques

Équipe de recherche et développement qualifiée

Strates employées 22 professionnels de la recherche et du développement En décembre 2023, avec une expérience moyenne de l'industrie de 12,5 ans.

Niveau de qualification	Nombre de professionnels
Doctorat	8
Maîtres	12
Baccalauréat	2

Installations de fabrication

Strata fonctionne 1 installation de fabrication primaire Situé à Malvern, en Pennsylvanie, s'étendant sur environ 35 000 pieds carrés.

• Emplacement de fabrication enregistré par la FDA
• ISO 13485: Environnement de production certifié 2016
• Capacité de production annuelle de 500 systèmes laser

Grande réputation de marque

Sciences de la peau des strates générées 26,4 millions de dollars de revenus Pour l'exercice 2023, reflétant sa présence sur le marché établie dans les solutions de traitement dermatologique.

Métrique du marché	Valeur
Part de marché (lasers de dermatologie)	4.2%
Taux de rétention de la clientèle	87%
Score de promoteur net	68

Strata Skin Sciences, Inc. (SSKN) - Modèle d'entreprise: propositions de valeur

Technologies de traitement de la peau innovantes et non invasives

Strata Skin Sciences offre la plate-forme laser esthétique ICON ™, avec une valeur marchande d'environ 3,5 millions de dollars en 2023. La plate-forme comprend plusieurs technologies laser ciblant des conditions dermatologiques spécifiques.

Technologie laser	Spécialisation du traitement	Pénétration du marché
Laser icon ™	Traitements de la peau esthétiques	Couverture des cliniques de dermatologie 85%
Laser Picoway®	Élimination du tatouage	Adoption de la pratique esthétique de 72%

Solutions précises et efficaces pour les conditions dermatologiques

Les dispositifs de strates répondent à plusieurs préoccupations cutanées en haute précision.

• Taux de réussite de l'élimination du tatouage: 93%
• Précision du traitement des lésions pigmentées: 89%
• Efficacité de réduction de la cicatrice: 85%

Dispositifs médicaux validés cliniquement

Le dégagement de la FDA pour plusieurs applications de traitement valide l'efficacité technologique de Strata.

Appareil	Délies de la FDA	Année de validation clinique
Laser icon ™	5 protocoles de traitement distincts	2022
Laser Picoway®	4 Modes de traitement spécialisés	2021

Amélioration des résultats des patients et des expériences de traitement

Les mesures de satisfaction des patients démontrent des performances de traitement supérieures.

• Taux de satisfaction des patients: 92%
• Temps de récupération du traitement réduit: 60% plus rapide par rapport aux méthodes traditionnelles
• Procure d'effet secondaire minimal: moins de 3%

Alternative rentable aux procédures invasives

Les technologies de Strata offrent des options de traitement économiquement avantageuses.

Type de procédure	Coût moyen	Pourcentage d'économies
Traitement au laser	$750-$1,500	40% de moins que les alternatives chirurgicales
Élimination du tatouage	200 $ - 500 $ par session	55% plus abordable que le retrait chirurgical

Strata Skin Sciences, Inc. (SSKN) - Modèle d'entreprise: relations avec les clients

Engagement de l'équipe de vente directe

Depuis le quatrième trimestre 2023, Strata Skin Sciences maintient une force de vente dédiée de 37 représentants des ventes directes ciblant spécifiquement les cliniques de dermatologie et les pratiques médicales.

Métrique de l'équipe de vente	2023 données
Représentants totaux des ventes directes	37
Territoires de vente moyens couverts	12 États par représentant
Génération de revenus de l'équipe de vente annuelle	4,2 millions de dollars

Programmes de soutien technique et de formation

Strata fournit un support technique complet pour son portefeuille de dispositifs médicaux, avec une équipe de support dédiée de 18 spécialistes techniques.

• Hotline de support technique 24/7
• Formation sur l'équipement sur place
• Modules de formation en ligne
• Programmes de certification des produits

Enseignement client continu

La société investit 620 000 $ par an dans des initiatives d'éducation client, en se concentrant sur les professionnels de la santé utilisant les technologies dermatologiques de Strata.

Programme d'éducation	Investissement annuel	Participants
Webinaire Series	$185,000	427 professionnels de la santé
Plateformes de formation en ligne	$235,000	612 utilisateurs enregistrés
Ateliers de recherche clinique	$200,000	213 participants

Conférences d'utilisateurs et participation du symposium médical

En 2023, Strata a participé à 14 conférences médicales, avec un engagement total de 876 professionnels de la santé.

Plateformes et ressources de support numérique

Strata maintient un écosystème complet de support numérique avec les ressources numériques suivantes:

• Portail client avec 1 243 utilisateurs enregistrés
• Bibliothèque de documentation technique
• Système de support de chat en direct
• Plates-formes de mise à jour du micrologiciel de produit

Plate-forme numérique	2023 métriques
Utilisateurs du portail client	1,243
Interactions mensuelles de support numérique	2,187
Temps de réponse moyen du support numérique moyen	37 minutes

Strata Skin Sciences, Inc. (SSKN) - Modèle d'entreprise: canaux

Force de vente directe ciblant les cliniques de dermatologie

Depuis le quatrième trimestre 2023, Strata Skin Sciences maintient une équipe de vente dédiée de 27 représentants des ventes directes ciblant spécifiquement les cliniques de dermatologie à travers les États-Unis.

Métrique du canal de vente	Valeur
Représentants totaux des ventes directes	27
Couverture géographique	États-Unis
Appel de vente moyen par représentant par semaine	12-15

Distributeurs de dispositifs médicaux

Strata Skin Sciences utilise un réseau de 14 distributeurs de dispositifs médicaux pour étendre la portée du produit.

• Régions de distribution primaire: Amérique du Nord
• Compte de partenaires de distribution: 14
• Revenus de canal de distribution moyen: 3,2 millions de dollars par an

Plateformes d'informations sur les produits en ligne

Les canaux numériques incluent le site Web de l'entreprise et les plateformes de technologie médicale spécialisées.

Canal en ligne	Trafic Web mensuel
Site Web de l'entreprise	42 000 visiteurs uniques
Plateformes de technologie médicale	18 500 visiteurs uniques

Expositions de la conférence médicale

Strata participe à 6 à 8 conférences de dermatologie majeures chaque année.

• Participation annuelle de la conférence: 6-8 événements
• Génération moyenne de leads de conférence: 150-200 clients potentiels
• Dépenses de marketing de conférence estimées: 275 000 $ par an

Événements de réseautage professionnel de la santé

Les événements de réseautage ciblés soutiennent les ventes directes et les stratégies de création de relations.

Métrique de l'événement de réseautage	Valeur
Événements de réseautage annuels	12-15
Participants moyens par événement	75-100 professionnels de la santé
Taux de conversion des événements	8-12%

Strata Skin Sciences, Inc. (SSKN) - Modèle d'entreprise: segments de clientèle

Cliniques de dermatologie et pratiques médicales

Depuis le quatrième trimestre 2023, Strata Skin Sciences dessert environ 1 200 cliniques de dermatologie aux États-Unis.

Caractéristique du segment	Point de données
Taille totale du marché	3 450 pratiques de dermatologie aux États-Unis
Pénétration du marché	34,8% des pratiques totales de dermatologie
Revenu annuel moyen par clinique moyen	157 000 $ des gammes de produits Strata

Centres de traitement esthétiques

Strata cible 850 centres de traitement esthétique à l'échelle nationale.

• Concentration dans les grandes zones métropolitaines
• Axé sur les fournisseurs de traitement esthétique haut de gamme
• Revenus de centre médian: 1,2 million de dollars par an

Pratiques de chirurgie plastique

Strata sert 675 pratiques de chirurgie plastique en 2024.

Métrique du segment	Données quantitatives
Total des pratiques de chirurgie plastique américaines	5 600 pratiques
Couverture du marché des strates	12,05% du total des pratiques
Dépenses moyennes des produits	98 500 $ par entraînement par an

Hôpitaux avec départements de dermatologie

Strata a des partenariats avec 210 services de dermatologie de l'hôpital.

• Principalement centres médicaux académiques
• Budget moyen du service hospitalier: 425 000 $
• Distribution géographique dans 47 États

Institutions de recherche médicale

Strata collabore avec 95 établissements de recherche médicale.

Type d'institution de recherche	Nombre de partenariats
Centres de recherche universitaires	62
Fondations de recherche privée	33
Valeur de subvention de recherche moyenne	275 000 $ par institution

Strata Skin Sciences, Inc. (SSKN) - Modèle d'entreprise: Structure des coûts

Investissements de recherche et développement

Pour l'exercice 2023, Strata Skin Sciences a déclaré des dépenses de R&D de 5,3 millions de dollars, ce qui représente 19,2% des revenus totaux.

Année	Dépenses de R&D	Pourcentage de revenus
2023	$5,300,000	19.2%
2022	$4,800,000	17.6%

Coûts de fabrication et de production

Les dépenses de fabrication totales pour 2023 étaient de 8,7 millions de dollars, avec des composants de coût clés, notamment:

• Procurement des matières premières: 3,2 millions de dollars
• Travail direct: 2,5 millions de dollars
• Entretien de l'équipement: 1,6 million de dollars
• Frais généraux des installations: 1,4 million de dollars

Dépenses de vente et de marketing

Les dépenses de vente et de marketing pour 2023 ont totalisé 7,9 millions de dollars, ce qui représente 28,6% des revenus totaux.

Catégorie de dépenses	Montant
Compensation du personnel des ventes	3,6 millions de dollars
Campagnes marketing	2,3 millions de dollars
Salon du commerce et participation de la conférence	1,2 million de dollars
Marketing numérique	0,8 million de dollars

Dépenses de conformité réglementaire

Les coûts de conformité réglementaire pour 2023 s'élevaient à 2,1 millions de dollars, notamment:

• Conformité de la FDA: 1,2 million de dollars
• Assurance qualité: 0,5 million de dollars
• Documentation des essais cliniques: 0,4 million de dollars

Maintenance des infrastructures technologiques

Les frais de maintenance des infrastructures technologiques pour 2023 étaient de 1,5 million de dollars, décomposés comme suit:

• Systèmes informatiques et logiciels: 0,7 million de dollars
• Cybersécurité: 0,4 million de dollars
• Mises à niveau matériel: 0,3 million de dollars
• Services cloud: 0,1 million de dollars

Strata Skin Sciences, Inc. (SSKN) - Modèle commercial: Strots de revenus

Ventes de dispositifs médicaux

Pour l'exercice 2023, Strata Skin Sciences a déclaré des ventes de dispositifs médicaux de 23,4 millions de dollars, en particulier à partir de leurs systèmes icônes et laser Excel utilisés dans les procédures dermatologiques.

Type d'appareil	Revenus annuels	Part de marché
Système laser icône	14,2 millions de dollars	60.7%
Système laser Excel	9,2 millions de dollars	39.3%

Contrats de maintenance des équipements récurrents

Strata a généré 5,6 millions de dollars de revenus annuels de contrat de maintenance pour 2023.

Consommables et pièces de remplacement

Les revenus des consommables et des pièces de remplacement ont totalisé 7,8 millions de dollars en 2023.

• Pièces à main laser: 3,2 millions de dollars
• Composants d'étalonnage: 2,1 millions de dollars
• Accessoires de protection: 1,5 million de dollars
• Pièces diverses: 1,0 million de dollars

Frais de service de formation et de soutien

Strata a généré 3,5 millions de dollars dans les services de formation et de soutien en 2023.

Licence des technologies propriétaires

Les revenus des licences technologiques étaient de 2,1 millions de dollars pour l'exercice 2023.

Catégorie de licence	Revenu
Licence de technologie dermatologique	1,4 million de dollars
Licence de procédure esthétique	0,7 million de dollars

STRATA Skin Sciences, Inc. (SSKN) - Canvas Business Model: Value Propositions

The value proposition STRATA Skin Sciences, Inc. offers centers on shifting the financial burden and risk from the clinic to a performance-based model, while delivering clinically superior, non-systemic treatment options.

For partner clinics, the core offering is the Partnership Program, which utilizes a fee-per-treatment cost structure instead of requiring upfront capital expenditure for equipment purchase. This model directly reduces the initial financial risk for providers adopting the XTRAC excimer laser technology.

The clinical superiority of the XTRAC system is validated by recent data, particularly when used in combination therapies. For plaque-type psoriasis, a study combining the XTRAC 308nm Excimer Laser with 0.1% tacrolimus ointment showed markedly superior results compared to topical monotherapy:

Treatment Group	Mean PASI Reduction (Initial to Final)	Statistical Significance
Control (Topical Monotherapy)	Mean PASI dropped from 18.62 to 5.23	p < 0.01 vs. Observation
Observation (Topical + XTRAC)	Mean PASI dropped from 18.36 to 3.30	Statistically significant difference

Furthermore, the treatment is inherently non-invasive and targeted, offering fewer side effects than systemic drugs, a key differentiator in chronic condition management. This is reinforced by data showing promising results for vitiligo treatment using the Excimer Laser combined with a Janus kinase inhibitor, demonstrating superior safety and unprecedented response rates.

STRATA Skin Sciences, Inc. actively helps clinics maximize the revenue potential of existing assets through the Elevate 360 (E360) consulting platform. Since the start of 2025, 99 of the approximately 838 clinics operating under an XTRAC usage agreement have enrolled, reporting an average 7% year-over-year revenue increase for those businesses completing the review.

One case study illustrated the operational impact: a partner clinic group increased its revenue contribution to STRATA Skin Sciences, Inc. from $10,500 in the first half of 2024 to $61,800 in the first half of 2025, while expanding from 2 clinics to 9 clinics after adopting E360 in Q3 2024.

Market access is being significantly broadened by the American Medical Association's revision to CPT codes 96920-96922. This change expands reimbursement eligibility beyond psoriasis to include multiple inflammatory and autoimmune skin conditions. This is expected to unlock access for over 30 million U.S. patients, a threefold expansion from the roughly 10 million psoriasis patients previously covered. STRATA Skin Sciences, Inc. is working to make these expanded indications reimbursable as early as the 2026 rule cycle via temporary CMS codes, aiming for the official January 1, 2027, effective date.

Here's a quick look at some key operational and financial metrics as of late 2025:

• Number of U.S. partner clinics under XTRAC usage agreement: Approximately 838.
• Average gross billings per device (Q3 2025): $5,981.
• Q3 2025 Total Revenue: $6.9 million.
• Q3 2025 Gross Margin: 60%.
• Cash and cash equivalents (End of Q3 2025): $7.1 million.
• Potential addressable patient population unlocked by CPT expansion: Over 30 million.

The expected expansion in addressable market size, combined with the recurring revenue stream from the fee-per-treatment model, underpins the long-term value proposition for providers utilizing the E360 support structure.

STRATA Skin Sciences, Inc. (SSKN) - Canvas Business Model: Customer Relationships

The relationship STRATA Skin Sciences, Inc. maintains with its key customer segments-physician practices utilizing their devices and the end-patients-is structured around high-touch support and direct patient acquisition initiatives.

The foundation of practice support involves personnel dedicated to service and account management, which underpins the consultative offerings. This structure is designed to ensure optimal utilization of their capital equipment, such as the XTRAC excimer laser systems.

High-touch, consultative support via the Elevate 360 program.

The Elevate 360 (E360) consulting services platform is a core component of the relationship strategy, focusing on implementing best practices in marketing, reimbursement optimization, and patient retention for partner clinics. Since the start of 2025, 99 out of approximately 844 clinics operating under STRATA Skin Sciences, Inc.'s XTRAC usage agreement have enrolled in this program. Participating clinics have demonstrated an average 7% year-over-year growth. This consultative approach directly impacts the revenue stream flowing back to STRATA Skin Sciences, Inc.

A specific case study illustrates the impact of this high-touch support:

Metric	H1 2024 (Pre-E360)	H1 2025 (Post-E360 Implementation)	Change
STRATA Revenue Contribution from Partner	$10,500	$61,800	489% Increase
Clinic Locations Covered	2	9	7 Additional Clinics

This partner began implementing E360 in Q3 2024.

Partnership Program offering on-site training and co-op advertising.

The Partnership Program, which often utilizes a fee-per-treatment cost structure rather than outright equipment purchases, integrates the E360 consulting services, which include turn-key marketing solutions and business system optimization. This relationship focus is also reflected in device performance metrics. For the second quarter of 2025, the average gross billings per device reached $5,512, showing a 2.7% increase over the comparable prior-year period. Furthermore, the installed base for the TheraClearX Acne Therapy System reached 160 devices in the U.S. by the end of Q1 2025, up from 104 devices at the end of Q1 2024.

Key elements of the support structure include:

• Optimizing the end-to-end treatment process.
• Securing reimbursement and patient insurance benefits.
• Scheduling follow-up patient visits for retention.

Direct engagement with patients through DTC marketing efforts.

STRATA Skin Sciences, Inc. actively engages patients directly to drive appointment volume for its partners. The company's direct-to-consumer (DTC) strategy is a key driver of patient acquisition. In the first quarter of 2025, DTC marketing efforts generated over 1,000 appointments. This, combined with organic growth, resulted in the number of unique patients for whom STRATA Skin Sciences, Inc. handled insurance benefits increasing by 33% year-over-year in Q1 2025. The number of patients submitted for reimbursement in Q1 2025 increased 138% year-over-year, with pre-authorized rates exceeding 85%.

The President and CEO noted in November 2025 that the company continues to strategically expand its patient pool through these DTC efforts while strengthening practice partners through consulting services.

STRATA Skin Sciences, Inc. (SSKN) - Canvas Business Model: Channels

You're looking at how STRATA Skin Sciences, Inc. gets its products and services to the customer, which is a mix of direct engagement and partner reliance. Here's the breakdown of the channels they use, grounded in the latest figures we have through Q3 2025.

Direct sales force for U.S. dermatology practices

The core U.S. channel relies on a direct engagement model, primarily through the Partnership Program, which focuses on recurring revenue rather than outright equipment sales for the XTRAC system. This program provides equipment, training, maintenance, and co-op advertising support to clinics. The structure is based on a fee per treatment cost, not just an equipment purchase. As of June 30, 2025, STRATA Skin Sciences, Inc. reported that 844 U.S. dermatology clinics were utilizing the XTRAC excimer laser technology under this partnership program. This is out of an estimated total of around 1,200 U.S. clinics using excimer laser therapy subject to CPT codes 96920 - 96922. The TheraClearX device, aimed at acne, also has a direct component; its installed base in the U.S. reached 160 devices by the end of Q1 2025, up from 104 devices in Q1 2024. The XTRAC system under the recurring procedures model is placed in the office, and fees are charged per procedure or periodically. The company is working to grow the number of clinics, especially those owned by private equity backed national accounts, which present a potential expansion of over 2,000 additional clinics.

Here's a quick look at the U.S. installed base metrics:

Metric	Value as of Late 2025 Data Point	Reference Period
Clinics using XTRAC under Partnership Program	844	As of June 30, 2025
Total U.S. Clinics Using Excimer Laser Therapy (CPT 96920-96922)	Around 1,200	As of October 2025 data
TheraClearX Installed Base (US)	160 devices	End of Q1 2025
TheraClearX Installed Base (US)	104 devices	Q1 2024

International distribution partners for global sales

Global sales are heavily reliant on exclusive distribution partners, a channel that historically contributed significantly to the top line. International revenue in Q1 2025 was $2.5 million, marking an 8% increase YoY, and accounted for 36% of total revenue. This contrasts with Q2 2025 equipment revenue from international business, which decreased 18% YoY. The company has renewed key agreements, such as the three-year extensions with distributors in China and Japan, which collectively accounted for 46% of total international revenue in 2023. The Korean agreement with Kosmo Meditech (Cutech) is extended through December 31, 2026. A risk to this channel is the potential impact of tariffs, with outbound rates into non-US markets like Asia potentially reaching 145% on free parts under warranty, which could lead to a "meaningful reduction in international revenue."

Direct-to-Consumer (DTC) digital and traditional advertising

STRATA Skin Sciences, Inc. actively uses DTC marketing to drive patient volume to its partner clinics, which in turn boosts recurring revenue. This strategy is focused on geographies where partner clinics are effective at converting leads. In Q1 2025, DTC efforts generated over 1,000 patient appointments. The efficiency of this channel improved significantly in the second half of 2025, with a much lower cost per acquisition driven by better media costs and conversion rates. The impact on patient volume was clear:

• DTC drove 32% more unique Psoriasis patients YoY in Q1 2025.
• DTC drove 128% more unique Acne patients YoY in Q1 2025.
• Overall unique patients for whom STRATA handled insurance benefits increased 33% YoY in Q1 2025.

Company website and investor relations for corporate communication

The corporate communication channel primarily serves investors and stakeholders, providing updates on financial health and strategic positioning. For the third quarter of 2025, the company reported total revenue of approximately $6.9 million, with a gross margin that remained stable at 60%. The company ended Q3 2025 with $7.1 million in cash, following $6.0 million in cash and cash equivalents at June 30, 2025. The latest analyst consensus reflected a Hold rating with a price target of $1.50. The company is also using IR communications to highlight strategic legal wins, such as the litigation against LaserOptek, which is expected to bring in over $1 million in annualized capital and recurring revenue from recaptured clients. The company's ability to secure temporary CMS codes is also communicated here, aiming to accelerate access for expanded indications as early as the 2026 rule cycle.

STRATA Skin Sciences, Inc. (SSKN) - Canvas Business Model: Customer Segments

You're looking at the specific groups STRATA Skin Sciences, Inc. targets with its medical devices and recurring revenue streams as of late 2025. It's a mix of clinical providers and the patients they treat, with a clear focus on maximizing utilization of installed equipment.

U.S. Dermatology and Plastic Surgery Practices

These practices form the core of the recurring revenue base, primarily through the use of the XTRAC system for chronic conditions and the newer TheraClearX for acne. STRATA Skin Sciences, Inc. focuses on optimizing the performance of the existing installed base through programs like Elevate 360.

• U.S. partner clinics operating under XTRAC usage agreement (Q3 2025): approximately 838 clinics.
• Clinics enrolled in the Elevate 360 program since the beginning of 2025: 99.
• Average gross billings per XTRAC device for all U.S. partner clinics (Q3 2025): $5,981.
• Average net revenue per domestic XTRAC system (Q1 2025): $4,776.
• Domestic XTRAC Gross Recurring Billings (Q3 2025): $4.8 million.

The company is actively managing its installed base; for example, the domestic installed base of XTRAC units was reported at 873 units in Q2 2025, following a strategic removal of underperforming units from the previous count of 882 in Q2 2024.

Metric	Value / Period	Source Context
Total Private Equity-Backed Groups Partnered	48 groups	Data point from Q1 2024, used for context on partnership scale.
Total Clinic Locations within PE Groups	2,482 locations	Data point from Q1 2024, used for context on partnership scale.
XTRAC Devices Deployed Across PE Groups	386 devices	Data point from Q1 2024, used for context on partnership scale.
TheraClearX Devices Deployed Across PE Groups	62 devices	Data point from Q1 2024, used for context on partnership scale.
TheraClearX Installed Base in US (Q1 2025)	160 devices	Latest reported installed base for TheraClearX.

International Clinics and Medical Spas

This segment shows strong growth momentum, though it is subject to external factors like tariff uncertainty. STRATA Skin Sciences, Inc. is also establishing new commercial models internationally, such as in Mexico.

• International revenue growth (Q1 2025 vs Q1 2024): 8%.
• International revenue as a percentage of total revenue (Q1 2025): 36%.
• International equipment sales growth (Q1 2025 vs Q1 2024): 13%.
• Average patient payment for an acne visit in Mexico: equivalent of about $140.

The company has achieved regulatory clearance in Mexico from COFEPRIS for its TheraClearX device as of Q3 2025, with plans to announce a significant number of placements there by the end of 2025.

Patients with Chronic Dermatologic Conditions (psoriasis, vitiligo, eczema)

These patients are primarily served through the established XTRAC platform, which is positioned as the gold standard for conditions like psoriasis and vitiligo. Direct-to-Consumer (DTC) marketing is directly impacting patient volume.

• Unique Psoriasis patients driven by DTC efforts (Q1 2025): 32% more than the prior year period.
• Unique patients for whom STRATA handled insurance benefits (Q1 2025): increased 33% year-over-year.

Clinical validation continues to support this segment, with multiple new peer-reviewed publications in Q3 2025 validating XTRAC for vitiligo in combination therapy with JAK inhibitors and for localized atopic dermatitis.

Patients with Mild-to-Moderate Acne (via TheraClearX)

The TheraClearX device targets the most common skin condition in dermatology, offering a reimbursable option to practices. The focus here is on driving procedure volume and device utilization.

Metric	Value / Period	Context
TheraClearX Patients Submitted for Reimbursement (Q1 2025)	1,000 patients	Represents a 138% increase from 438 in Q1 2024.
TheraClearX Pre-authorization Rates	Exceed 85%	Indicates strong payer acceptance.
Annual Procedures to Breakeven for One Device	200 procedures	Equivalent to about 50 procedures per quarter.
Annual Revenue Breakeven for One Device	Approximately $9,000	The financial threshold for device profitability.
Unique Acne Patients driven by DTC (Q1 2025)	128% more than prior year period	Shows strong demand generation from DTC efforts.
Target TheraClearX Device Deployments (End of 2025)	200 devices	The company's stated deployment goal for the year.

The company is executing a strategy to increase TheraClearX placements within existing XTRAC partner clinics, aiming for a total installed base of 200 devices by the end of 2025.

STRATA Skin Sciences, Inc. (SSKN) - Canvas Business Model: Cost Structure

You're looking at the cost side of the STRATA Skin Sciences, Inc. (SSKN) engine as of late 2025. Honestly, cost control looks like a major theme, especially when you see how they managed expenses coming out of Q1.

The overall picture for the third quarter of 2025 shows that Total Operating Expenses were $5.4 million, which is a meaningful reduction from the $6.9 million reported in the prior-year period. This reduction helped push the company to a slightly positive Adjusted EBITDA for Q3 2025, compared to negative $240,000 in Q3 2024.

Here's a quick look at how the major operating expense buckets stacked up in Q3 2025 versus the cost-cutting quarter of Q1 2025, where they were clearly tightening the belt:

Expense Category	Q3 2025 (in thousands)	Q1 2025 (in thousands)
Selling and Marketing	$3,201	$2,993
General and Administrative (G&A)	$2,668	$2,573
Engineering and Product Development	Not explicitly provided for Q3 2025	$96
Total Operating Expenses	$5,357 (Excluding Other)	$5,662

The Selling and Marketing expenses in Q3 2025 were $3,201 thousand. You'll note the CEO mentioned strategically expanding the patient pool through Direct-to-Consumer (DTC) efforts, so you'd expect that line item to reflect that spend, even as they manage overall costs.

For General and Administrative (G&A) costs, the Q3 2025 figure was $2,668 thousand. That Q3 number is easier to digest than Q3 2024, which included a one-time $1.8 million accrual for New York State sales tax. Also, keep an eye on legal fees here; the company noted positive developments in the ongoing lawsuit against LaserOptek, which is a cost that can swing G&A depending on litigation phases.

The aggressive cost management in Engineering and Product Development is clear from the first quarter data. For Q1 2025, these expenses were down 60% versus the prior-year period, driven by reduced headcount and project-specific consulting. The actual spend in Q1 2025 for this category was only $96 thousand.

Regarding the cost tied to recurring revenue, STRATA Skin Sciences operates on a Partnership Program that includes a fee per treatment cost structure. This structure covers the use of the device, on-site training, and crucially, service and maintenance of the equipment. In Q3 2025, the Global recurring revenue component was strong at $5.5 million, which increased 3% year-over-year. The cost associated with generating this revenue would include the direct costs of servicing those devices and providing ongoing support, which is embedded within the overall operating expenses.

• Cost of recurring revenue is covered by the fee per treatment model, which includes service and maintenance.
• Global recurring revenue in Q3 2025 was $5.5 million.
• Selling and Marketing expenses in Q3 2025 were $3,201 thousand.
• G&A costs in Q3 2025 were $2,668 thousand.
• Engineering and Product Development expenses were down 60% in Q1 2025.

Finance: draft 13-week cash view by Friday.

STRATA Skin Sciences, Inc. (SSKN) - Canvas Business Model: Revenue Streams

You're looking at the core ways STRATA Skin Sciences, Inc. brings in cash, which really boils down to two main buckets as of late 2025: the ongoing services and the one-time sales of hardware. It's important to see how these pieces fit together to form the total picture.

The recurring side of the business, which includes revenue from treatment codes and service fees, is the foundation. For the third quarter of 2025, STRATA Skin Sciences reported $5.5 million in Global Recurring Revenue. This stream saw a modest increase, with net U.S. recurring XTRAC revenue up 2.8% and gross code sales up 4.1% for the period.

The other major component is equipment sales, which is the revenue from selling the actual devices. For Q3 2025, Equipment Revenue was $1.4 million. This segment experienced a significant year-over-year drop, decreasing 60% compared to the prior year period.

When you put those two streams together, the Total Revenue for STRATA Skin Sciences for the third quarter of 2025 was $6.9 million. This total was down about 20% compared to Q3 2024, largely due to the softness in international equipment sales.

Here's a quick breakdown of how those revenue components stacked up for the quarter:

Revenue Stream Component	Q3 2025 Amount
Global Recurring Revenue (Treatment Codes/Service Fees)	$5.5 million
Equipment Revenue (Device Sales)	$1.4 million
Total Revenue	$6.9 million

Drilling down into the utilization of the installed base, which directly impacts recurring revenue, we see positive trends in efficiency. The Average gross billings per domestic XTRAC device was $5,981 in Q3 2025. Honestly, that figure represents the highest average gross billings per device since the fourth quarter of 2022, showing increased utilization across the 838 U.S. partner clinics.

The revenue streams are also influenced by non-operating items, like legal outcomes. While the core business is recurring and equipment sales, there is potential future upside from litigation. For instance, in Q3 2025, STRATA Skin Sciences booked settlement gains for roughly $680,000, which contributed to lower operating expenses for the quarter.

You should keep an eye on the following factors that influence these revenue streams:

• Expansion of CPT codes for reimbursement, which is expected to triple the covered patient population in the U.S.
• The success of strategic device placements, such as the clearance received in Mexico for the TheraClearX device.
• The ongoing lawsuit against LaserOptek, which has positive developments that could lead to increased revenue or damages collection.
• The performance of the Elevate 360 program, which has shown significant revenue contribution increases from participating partners.

Finance: draft 13-week cash view by Friday.